Literature DB >> 8590953

Study of serum 3,5,3'-triiodothyronine sulfate concentration in patients with systemic non-thyroidal illness.

F Santini1, L Chiovato, L Bartalena, P Lapi, R Palla, V Panichi, F Velluzzi, L Grasso, I J Chopra, E Martino, A Pinchera.   

Abstract

Sulfation is an important pathway of triiodothyronine (T3) metabolism. Increased serum T3 sulfate (T3S) values have been observed during fetal life and in pathological conditions such as hyperthyroidism and selenium deficiency. Similar variations have also been reported in a small number of patients with systemic non-thyroidal illness, but the underlying mechanisms have not been elucidated. In this study, serum T3S concentrations have been measured by a specific radioimmunoassay in 28 patients with end-stage neoplastic disease (ESND) and in 44 patients with chronic renal failure (CRF); 41 normal subjects served as controls. Both ESND and CRF patients had lower serum total T4 (TT4) and total T3 (TT3) than normal controls, while serum reverse T3 (rT3) was increased significantly in ESND (0.7 +/- 0.5 nmol/l; p < 0.001 vs. controls) but not in CRF (0.3 +/- 0.1 nmol/l). The TT3/rT3 ratio, an index of type I iodothyronine monodeiodinase (type I MD) activity, was reduced significantly in both groups of patients. Serum T4-binding globulin (TBG) was decreased in CRF but not in ESND patients. Serum T3S was significantly higher both in ESND (71 +/- 32 pmol/l) and CRF (100 +/- 24 pmol/l) than in controls (50 +/- 16 pmol/l, p < 0.001). Serum T3S values showed a positive correlation with rT3 values and a negative correlation with both TT3 and FT3 values in ESND, but not in CRF. In the latter group a positive correlation was observed between T3S and TBG values. The T3S/FT3 ratio was higher both in CRF (18 +/- 5) and in ESND (23 +/- 18) as compared to controls (10 +/- 4). Serum inorganic sulfate was increased and correlated positively with T3S values in CRF patients. In conclusion, the results of this study in a large series of patients confirm that patients with systemic non-thyroidal illness have increased serum T3S levels. The mechanisms responsible for these changes appear to be different in ESND and CRF patients. In ESND the increase in serum T3S levels is mainly related to reduced degradation of the hormone by type I MD, whereas in CRF it might be driven by the enhanced sulfate ion concentration, and could be partially dependent on the impaired renal excretion of T3S. Because T3S can be reconverted to T3, it is possible that increased T3S concentrations contribute to maintenance of the euthyroid state in systemic non-thyroidal disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8590953     DOI: 10.1530/eje.0.1340045

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  Detection and quantification of 3,5,3'-triiodothyronine and 3,3',5'-triiodothyronine by electrospray ionization tandem mass spectrometry.

Authors:  Yuntao Zhang; Abigail H Conrad; Gary W Conrad
Journal:  J Am Soc Mass Spectrom       Date:  2005-09-22       Impact factor: 3.109

2.  Leptin regulation of core body temperature involves mechanisms independent of the thyroid axis.

Authors:  Jennifer D Deem; Kenjiro Muta; Kayoko Ogimoto; Jarrell T Nelson; Kevin R Velasco; Karl J Kaiyala; Gregory J Morton
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-06-26       Impact factor: 4.310

Review 3.  [Non-thyroid illness" or changed thyroid hormone parameter syndrome with non-thyroid illnesses].

Authors:  W Reinhardt; K Mann
Journal:  Med Klin (Munich)       Date:  1998-11-15

Review 4.  A Review of the Pharmacokinetics of Levothyroxine for the Treatment of Hypothyroidism.

Authors:  Philippe Colucci; Corinne Seng Yue; Murray Ducharme; Salvatore Benvenga
Journal:  Eur Endocrinol       Date:  2013-03-15

5.  Treatment of Hypothyroid Patients With L-Thyroxine (L-T4) Plus Triiodothyronine Sulfate (T3S). A Phase II, Open-Label, Single Center, Parallel Groups Study on Therapeutic Efficacy and Tolerability.

Authors:  Ferruccio Santini; Giovanni Ceccarini; Caterina Pelosini; Monica Giannetti; Ilaria Ricco; Giorgia Querci; Enzo Grossi; Giorgio Saponati; Paolo Vitti
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-29       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.